This study is testing a new treatment combination for people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or transformed lymphoma. Researchers want to see if combining glofitamab, polatuzumab, and obinutuzumab with standard treatment (rituximab, cyclophosphamide, doxorubicin, and prednisone) is effective and has manageable side effects. You may be able to join if you are 65 to 79 years old and considered unfit or frail, or if you are 80 years or older. You must not have had prior treatment for your lymphoma. The main goal is to see how many people have a complete response (meaning the cancer is no longer detectable) after one year. This study plans to enroll 42 participants, but its current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. The study plans to enroll 42 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will evaluate the complete response rate at 1 year, suggesting follow-up for at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.